Shionogi debuts Mulpleo in the UK

9 March 2020

The European subsidiary of Japanese drugmaker Shionogi (TYO: 4507) today said it has launched its Mulpleo (lusutrombopag) in the UK for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) undergoing invasive procedures.

Mulpleo is the first licensed treatment available on the National Health Service (NHS) in the UK to treat this condition and has also been approved for funding across the health services in England and Wales, Scotland and Northern Ireland.

Chronic liver disease is a huge burden in the UK; over 600,000 people have a form of serious liver disease and 60,000 have cirrhosis, commented Shionogi. The number of deaths has increased by 400% since 1970 and it is now responsible for the highest number of premature deaths in 35-49 year olds. Currently, the only option available to doctors and their patients to manage platelet counts is a transfusion of platelets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK